Cabaletta Bio

Cabaletta Bio

Cabaletta Bio

Cabaletta Bio has adapted clinicallyvalidated and FDAapproved CAR T cell technology to target B cellmediated autoimmune diseases with its CAAR T cell technology.
Founded
2017
Raised
$50M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$50,000,000
Venture capital (Series B) - 2019
Redmile Group Adage Capital Management 5AM Ventures +3
Team Size
1–10
Employees
Technical.ly Philly

University City biotech firm Cabaletta Bio Inc. goes public in $74.8M IPO

PE HUB

VC-backed Cabaletta Bio begins trading on NASDAQ

$50,000,000 Venture capital (Series B)
MedCity News , FinSMEs

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies